MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526036 | Name: Clofibride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clofibride is a hypolipaemic agent, reducing hypertriglyceridemia and hypercholesterolemia.

Chemical Structure

Clofibride
Clofibride
CAS#26717-47-5

Theoretical Analysis

MedKoo Cat#: 526036

Name: Clofibride

CAS#: 26717-47-5

Chemical Formula: C16H22ClNO4

Exact Mass: 327.1237

Molecular Weight: 327.81

Elemental Analysis: C, 58.63; H, 6.76; Cl, 10.81; N, 4.27; O, 19.52

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Clofibride
IUPAC/Chemical Name
[4-(Dimethylamino)-4-oxobutyl] 2-(4-chlorophenoxy)-2-methylpropanoate
InChi Key
CXQGFLBVUNUQIA-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3
SMILES Code
CC(C)(OC1=CC=C(Cl)C=C1)C(OCCCC(N(C)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 327.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Magalhaes NS, Fessi H, Puisieux F, Benita S, Seiller M. An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride. J Microencapsul. 1995 Mar-Apr;12(2):195-205. PubMed PMID: 7629662. 2: Romics L. [Basic principles of drug therapy of hyperlipoproteinemia]. Orv Hetil. 1988 Nov 6;129(45):2391-9. Review. Hungarian. PubMed PMID: 3054710. 3: Elsair J, Tabet Aoul M, Dahmani Y, Dufour P, Khelfat K. [Effects of clofibride upon lipolysis from normal rat adipocytes in vitro (author's transl)]. J Pharmacol. 1982 Jan-Mar;13(1):43-8. French. PubMed PMID: 7040821. 4: Elsair J, Marquie G, Tabet Aoul M, Dahmani Y, Tabet Aoul FS, Dufour P, Khelfat K, Iklef F, Ghouini A. [Effect of clofibride on the lipolysis of perirenal adipose tissue in hyperlipemic rabbits]. C R Seances Soc Biol Fil. 1982;176(2):146-50. French. PubMed PMID: 6212099. 5: Elsair J, Marquie G, Drif M, Khelfat K, Benouniche N, Tabet Aoul M, Tabet Aoul FS, Iklef F, Ghouini A. [Potentiation by clofibride of the heparin-induced clearing reaction (intravascular hydrolysis of neutral lipids), in hyperlipemic rabbits]. C R Seances Soc Biol Fil. 1982;176(2):140-5. French. PubMed PMID: 6212098. 6: Loiseau GP, Millischer RJ, Lohier PY, Mardiguian JS, Gilede AM, Ginocchio AV. On the metabolism of clofibride, a hypolipaemic drug. J Pharm Pharmacol. 1980 Jul;32(7):483-8. PubMed PMID: 6105184. 7: Elsair J, Drif M, Merad R, Denine R, Khelfat K, Benouniche N, Reggabi M, Alamir B. [Effects of clofibride in the rabbit or in normal man, at the beginning or after 15 days of treatment. Effects on plasma lipids in the hours following its administration during fasting, without heparin or during heparin-clearing factor induction]. Biomedicine. 1979 Nov;30(5):249-56. French. PubMed PMID: 518959. 8: Rozé C, Cuchet P, Souchard M, Vaille C, Debray C. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat. Eur J Pharmacol. 1977 May 1;43(1):57-64. PubMed PMID: 862664. 9: Harvengt C, Desager JP. Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol Biopharm. 1977 Jan;15(1):1-4. PubMed PMID: 576423. 10: Fromantin M, Garraud R, Auriche M. [Medium and long term study of clofibride in the treatment of atherogenic hyperlipidemia. Statistical approach to the results]. Sem Hop Ther. 1976 Nov;52(9):455-64. French. PubMed PMID: 1006320. 11: Harvengt C, Desager JP. Pharmacokinetic study and bioavailability of three marketed compounds releasing p-chlorophenoxyisobutyric acid (CPIB) in volunteers. Int J Clin Pharmacol Biopharm. 1976 Sep;14(2):113-8. PubMed PMID: 1002348. 12: Leutenegger M, Choisy H, Caron J, Paris H. [Treatment of hyperlipidemias. Value of a new hypolipidemic drug clofibride, (M-G. 46)]. Therapie. 1974 Jul-Aug;29(4):599-610. French. PubMed PMID: 4439371. 13: Warembourg H, Jaillard J. [Clinical experimentation of clofibride. Apropos of 40 cases]. Lille Med. 1973 Dec;18(10 Suppl 5):suppl 5:1292-6. French. PubMed PMID: 4802928.